Dostarlimab
Generic name: Dostarlimab
Brand names: Jemperli
Dosage form: intravenous solution (gxly 500 mg/10 mL)
Drug class:
Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
Usage of Dostarlimab
Dostarlimab is used to treat adults with certain cancers after other treatments did not work or stopped working, and/or the cancer has returned, or it has spread or cannot be removed by surgery.
Your doctor will make sure you have the correct tumor type to be treated with dostarlimab.
Dostarlimab may also be used for purposes not listed in this medication guide.
Dostarlimab side effects
Get emergency medical help if you have signs of an allergic reaction (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).
Some side effects may occur during the injection. Tell your caregiver if you feel light-headed, chilled or feverish, itchy, or short of breath.
Dostarlimab strengthens your immune system to help it attack cancer cells, but it may also attack healthy cells and you could develop serious or fatal side effects.
Dostarlimab may cause serious side effects. Call your doctor at once if you have:
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects of dostarlimab may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Dostarlimab
Tell your doctor if you have ever had:
May harm an unborn baby. You may need a pregnancy test to make sure you are not pregnant. Use birth control while using dostarlimab and for at least 4 months after your last dose. Tell your doctor if you become pregnant.
Do not breastfeed while using dostarlimab, and for at least 4 months after your last dose.
Relate drugs
- Atezolizumab
- Avelumab
- Bavencio
- Cemiplimab
- Cemiplimab-rwlc
- Dostarlimab
- Dostarlimab-gxly
- Durvalumab
- Imfinzi
- Jemperli
- Keytruda
- Libtayo
- Nivolumab
- Opdivo
- Pembrolizumab
- Retifanlimab
- Retifanlimab-dlwr
- Tecentriq
- Zynyz
How to use Dostarlimab
Usual Adult Dose for Endometrial Carcinoma:
Initial dose: -Dose 1 through Dose 4: 500 mg IV over 30 minutes every 3 weeks Maintenance dose:-Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1000 mg IV over 30 minutes every 6 weeks Duration of therapy:-Until disease progression or unacceptable toxicityUse: For the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an approved test, that has progressed on or following prior treatment with a platinum-containing regimen and are not candidates for curative surgery or radiation
Usual Adult Dose for Solid Tumors:
Initial dose: -Dose 1 through Dose 4: 500 mg IV over 30 minutes every 3 weeks Maintenance dose:-Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1000 mg IV over 30 minutes every 6 weeks Duration of therapy:-Until disease progression or unacceptable toxicityComment:-This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).Use: For the treatment of solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options
Warnings
Call your doctor at once if you have new or worsening symptoms such as: cough, chest pain, breathing problems, severe stomach pain, diarrhea, bloody or tarry stools, headaches, confusion, severe weakness, vision problems, decreased urination, bruising or bleeding, blood in your urine, dark urine, or yellowing of the skin or eyes.
What other drugs will affect Dostarlimab
Other drugs may affect dostarlimab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions